Sweden

As of June 2026, the HTA Center of the Västra Götaland Region in Sweden is conducting six health technology assessments across areas such as gynecology, orthopedics, neurology, and in-vitro diagnostics.

From June 1, 2026, certain responsibilities will be transferred from the National Board of Health and Welfare (Socialstyrelsen) to the Swedish eHealth Agency (E-hälsomyndigheten). These include responsibility for managing classifications, including procedure coding (KVA) and diagnosis coding (ICD-10-SE). Responsibility for the diagnosis-related groups (DRG) system will remain with the National Board of Health and Welfare.

In February 2026, the Swedish Medical Technologies Product (MTP) Council issued two recommendations to Swedish regions within the national framework for the Orderly Introduction of Medical Technologies. The first recommendation concerns MR-guided focused ultrasound (Exablate Prime), which is recommended for patients with severe essential tremor. The second is an interim recommendation advising regions to refrain from introducing diagnostic blood tests for Alzheimer’s disease until the MTP Council has conducted a comprehensive assessment and issued final recommendations.

In November 2025, the annual update of the Swedish NordDRG system was published to come into force on January 1, 2026. Five new DRGs were introduced. In 2026, to obtain DRG tariffs, individual DRG cost weights must be multiplied by a base rate of 81,142 SEK.

On October 27, 2025, the annual update of the Swedish procedure coding system (KVÅ) was released to come into force on January 1, 2026. A total of 35 new surgical (KKÅ) procedure codes were added in the fields of nephrology and urology, obstetrics and gynecology, interventional radiology, men’s health, and radiotherapy. Furthermore, 90 new medical (KMÅ) procedure codes were introduced concerning diagnostic imaging, radiology, gastrointestinal, and other fields.

In October 2025, the Swedish Dental and Pharmaceutical Benefits Agency (TLV) launched two new thematic horizon scans focusing on cancer care. The scans aim to identify innovative medical technologies that may be evaluated within the national Orderly introduction framework for medical technologies. Stakeholders, including industry representatives, are invited to submit proposals by November 30, 2025.

On October 20, 2025, Genomic Medicine Sweden (GMS) announced the launch of five strategic development projects aimed at extending access to advanced diagnostics nationwide. The projects will focus on updating national GMS gene panel (big NGS panel for solid tumors), liquid biopsies, cell-free tumor DNA (ctDNA) for diagnosis and follow-up of metastatic breast cancer, gene panels for hepatopancreatobiliary (HPB) cancer, and improving diagnosis of sarcoma.

As of October 2025, the Swedish Dental and Pharmaceutical Benefits Agency is working on health technology assessments in several areas, including endocrine, e-health, and neurology procedures.

As of September 2025, the Swedish Agency for Health Technology Assessment and Assessment of Social Services is working on health technology assessments in several areas, including in-vitro diagnostics, e-health, and gynecology procedures.

As of August 2025, the Centre for Assessment of Medical Technology in Örebro region in Sweden is working on health technology assessments in several areas, including in-vitro diagnostics, neuromodulation, and orthopedics.

In June 2025, the Skåne University Hospital (HTA South) is working on health technology assessments in several areas, including diagnostic imaging, e-health, in-vitro diagnostics, men’s health and neurology.

On May 8, 2025, the Medical Technologies Product (MTP) Council revised its recommendations on continuous glucose monitoring (CGM) for patients with type 2 diabetes (T2D), initially issued in 2022 under the Orderly Introduction of Medical Technologies framework. The updated recommendations now allow the use of other CGM devices considered equivalent to FreeStyle Libre and FreeStyle Libre 2, which were the only recommended products in 2022. Simultaneously, the MTP Council initiated a reassessment of CGM devices for T2D and tasked the Dental and Pharmaceutical Benefits Agency (TLV) to carry out a new health economic evaluation.